Åke Berglund

The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer: A post-hoc exploratory analysis of the randomized NORDIC9-study

Liposits, Gabor; Winther, Stine B.; Ryg, Jesper; Skuladottir, Halla et al.

Ingår i Journal of Geriatric Oncology, 2024

• DOI för The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer: A post-hoc exploratory analysis of the randomized NORDIC9-study
• Ladda ner fulltext (pdf) av The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer: A post-hoc exploratory analysis of the randomized NORDIC9-study

Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study

Liposits, Gabor; Ryg, Jesper; Skuladottir, Halla; Winther, Stine B. et al.

Ingår i Journal of Geriatric Oncology, 2023

• DOI för Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study
• Ladda ner fulltext (pdf) av Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study

Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

Dijkstra, Esmee A.; Nilsson, Per J.; Hospers, Geke A. P.; Bahadoer, Renu R. et al.

Ingår i Annals of Surgery, 2023

• DOI för Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer

Falk, Philip; Severin, Mira; Berglund, Åke; Guren, Marianne G. et al.

Ingår i Cancer Treatment and Research Communications, 2022

• DOI för Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
• Ladda ner fulltext (pdf) av Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer

The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study

Liposits, Gabor; Skuladottir, Halla; Ryg, Jesper; Winther, Stine Braendegaard et al.

Ingår i Journal of Clinical Medicine, 2022

• DOI för The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study
• Ladda ner fulltext (pdf) av The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study

The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer: A post-hoc exploratory analysis of the randomized NORDIC9-study

Liposits, Gabor; Winther, Stine B.; Ryg, Jesper; Skuladottir, Halla et al.

Ingår i Journal of Geriatric Oncology, 2024

• DOI för The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer: A post-hoc exploratory analysis of the randomized NORDIC9-study
• Ladda ner fulltext (pdf) av The effect of BRAF^V600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer: A post-hoc exploratory analysis of the randomized NORDIC9-study

Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study

Liposits, Gabor; Ryg, Jesper; Skuladottir, Halla; Winther, Stine B. et al.

Ingår i Journal of Geriatric Oncology, 2023

• DOI för Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study
• Ladda ner fulltext (pdf) av Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study

Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

Dijkstra, Esmee A.; Nilsson, Per J.; Hospers, Geke A. P.; Bahadoer, Renu R. et al.

Ingår i Annals of Surgery, 2023

• DOI för Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer

Falk, Philip; Severin, Mira; Berglund, Åke; Guren, Marianne G. et al.

Ingår i Cancer Treatment and Research Communications, 2022

• DOI för Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
• Ladda ner fulltext (pdf) av Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer

The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study

Liposits, Gabor; Skuladottir, Halla; Ryg, Jesper; Winther, Stine Braendegaard et al.

Ingår i Journal of Clinical Medicine, 2022

• DOI för The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study
• Ladda ner fulltext (pdf) av The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study

Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy: The Randomized NORDIC9-Study

Liposits, Gabor; Eshoj, Henrik Rode; Möller, Sören; Braendegaard Winther, Stine et al.

Ingår i Cancers, 2021

• DOI för Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy: The Randomized NORDIC9-Study
• Ladda ner fulltext (pdf) av Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy: The Randomized NORDIC9-Study

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

Whither, Stine Braendegaard; Liposits, Gabor; Skuladottir, Haifa; Hofsli, Eva et al.

Ingår i The Lancet Gastroenterology & Hepatology, s. 376-388, 2019

• DOI för Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9

Winther, Stine Braendegaard; Österlund, Pia; Berglund, Åke; Glimelius, Bengt et al.

Ingår i BMC Cancer, 2017

• DOI för Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
• Ladda ner fulltext (pdf) av Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9

Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial

Erlandsson, Johan; Holm, Torbjörn; Pettersson, David; Berglund, Åke et al.

Ingår i The Lancet Oncology, s. 336-346, 2017

• DOI för Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

Hagman, H.; Frodin, J. -E; Berglund, Åke; Sundberg, J. et al.

Ingår i Annals of Oncology, s. 140-147, 2016

• DOI för A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

NORDIC9: A randomized phase II trial exploring treatment of older patients with metastatic colorectal cancer (mCRC) by comparing full dose monotherapy (S-1 followed by irinotecan) with reduced combination regimen (S-1/oxaliplatin followed by S-1/irinotecan)

Winther, S. B.; Osterlund, P.; Berglund, Åke; Glimelius, Bengt et al.

Ingår i Annals of Oncology, 2016

• DOI för NORDIC9: A randomized phase II trial exploring treatment of older patients with metastatic colorectal cancer (mCRC) by comparing full dose monotherapy (S-1 followed by irinotecan) with reduced combination regimen (S-1/oxaliplatin followed by S-1/irinotecan)

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Berglund, Åke; Ullen, Anders; Lisyanskaya, Alla; Orlov, Sergey et al.

Ingår i Investigational new drugs, s. 1232-1241, 2015

• DOI för First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial

Breugom, A. J.; van Gijn, W.; Muller, E. W.; Berglund, Åke et al.

Ingår i Annals of Oncology, s. 696-701, 2015

• DOI för Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial

A randomized pilot study with daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer

Backman, Malin; Wengstrom, Yvonne; Johansson, Birgitta; Sköldengen, Ida et al.

Ingår i Acta Oncologica, s. 510-520, 2014

• DOI för A randomized pilot study with daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer

The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab

Berglund, Åke; Willen, Linda; Grodeberg, Lina; Skattum, Lillemor et al.

Ingår i Acta Oncologica, s. 1212-1220, 2014

• DOI för The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial

Johnsson, A.; Hagman, H.; Frodin, J. -E; Berglund, Åke et al.

Ingår i Annals of Oncology, s. 2335-2341, 2013

• DOI för A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial

Daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer - a randomized pilot study

Malin, M. Backman; Yvonne, Y. Wengstrom; Johansson, Birgitta; Skoldengen, Ida et al.

Ingår i European Journal of Cancer, 2013

Health-related quality of life in patients with metastatic colorectal cancer receiving palliative combination chemotherapy

Byström, Per; Johansson, Birgitta; Berglund, Åke; Sorbye, H et al.

2012

Evaluation of predictive markers for patients with advanced colorectal cancer

Byström, Per; Berglund, Åke; Nygren, Peter; Wernroth, Lisa et al.

Ingår i Acta Oncologica, s. 849-859, 2012

• DOI för Evaluation of predictive markers for patients with advanced colorectal cancer

The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy

Suzuki, C; Blomqvist, L; Sundin, Anders; Jacobsson, H et al.

Ingår i Annals of Oncology, s. 948-954, 2012

• DOI för The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy

Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer: Long-term results from a phase III study

Brændengen, Morten; Tveit, Kjell M; Hjermstad, Marianne J; Johansson, Hemming et al.

Ingår i European Journal of Cancer, s. 813-819, 2012

• DOI för Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer: Long-term results from a phase III study

Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer

Frederiksen, C.; Qvortrup, C.; Christensen, I. J.; Glimelius, Bengt et al.

Ingår i Annals of Oncology, s. 369-375, 2011

• DOI för Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

Glimelius, Bengt; Garmo, Hans; Berglund, Åke; Fredriksson, L. A. et al.

Ingår i The Pharmacogenomics Journal, s. 61-71, 2011

• DOI för Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: Results from a randomized phase III study

Braendengen, Morten; Tveit, Kjell Magne; Bruheim, Kjersti; Cvancarova, Milada et al.

Ingår i International Journal of Radiation Oncology, Biology, Physics, s. 1017-1024, 2011

• DOI för Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: Results from a randomized phase III study

Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study

Glimelius, Bengt; Spindler, K. L.; Frödin, J-E.; Berglund, Åke et al.

Ingår i Annals of Oncology, s. 1127-1128, 2010

• DOI för Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study

High Plasma TIMP-1 and Serum CEA Levels during Combination Chemotherapy for Metastatic Colorectal Cancer Are Significantly Associated with Poor Outcome

Aldulaymi, Bahir; Byström, Per; Berglund, Åke; Christensen, Ib J. et al.

Ingår i Oncology, s. 144-149, 2010

• DOI för High Plasma TIMP-1 and Serum CEA Levels during Combination Chemotherapy for Metastatic Colorectal Cancer Are Significantly Associated with Poor Outcome

An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer

Berglund, Åke; Byström, Per; Johansson, Birgitta; Nygren, Peter et al.

Ingår i Medical Oncology, s. 65-72, 2010

• DOI för An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data

von Heideman, Anne; Berglund, Åke; Larsson, Rolf; Nygren, Peter

Ingår i Cancer Chemotherapy and Pharmacology, s. 1165-1172, 2010

• DOI för Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data

Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial

Gubanski, Michael; Johnsson, Anders; Fernebro, Eva; Kadar, Lianna et al.

Ingår i Gastric Cancer, s. 155-161, 2010

• DOI för Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial

A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer

Glimelius, Bengt; Lahn, M.; Gawande, S.; Cleverly, A. et al.

Ingår i Annals of Oncology, s. 1020-1026, 2010

• DOI för A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer

An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer

Byström, P.; Berglund, Åke; Nygren, Peter; Wernroth, Mona-Lisa et al.

Ingår i Oncology Reports, s. 1645-1652, 2010

• DOI för An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer

Serum vitamin B12 and folate status among patients with chemotherapy treatment for advanced colorectal cancer

Byström, Per; Björkegren, Karin; Larsson, Anders; Johansson, Linda et al.

Ingår i Upsala Journal of Medical Sciences, s. 160-164, 2009

• DOI för Serum vitamin B12 and folate status among patients with chemotherapy treatment for advanced colorectal cancer

Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study

Gunnlaugsson, Adalsteinn; Anderson, Harald; Fernebro, Eva; Kjellén, Elisabeth et al.

Ingår i European Journal of Cancer, s. 807-813, 2009

• DOI för Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study

A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer

Glimelius, Bengt; Sørbye, H; Balteskard, L; Byström, P et al.

Ingår i Annals of Oncology, s. 909-914, 2008

• DOI för A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer

Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil

Qvortrup, Camilla; Yilmaz, M.; Ogreid, D.; Berglund, Åke et al.

Ingår i Annals of Oncology, s. 1154-9, 2008

• DOI för Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil

Short-course preoperative radiotherapy with delayed surgery in rectal cancer: a retrospective study

Radu, Calin; Berglund, Åke; Påhlman, Lars; Glimelius, Bengt

Ingår i Radiotherapy and Oncology, s. 343-9, 2008

• DOI för Short-course preoperative radiotherapy with delayed surgery in rectal cancer: a retrospective study

Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer

Braendengen, Morten; Tveit, Kjell M.; Berglund, Åke; Birkemeyer, Elke et al.

Ingår i Journal of Clinical Oncology, s. 3687-3694, 2008

• DOI för Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer

Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?

Berglund, Åke; Cedermark, B; Glimelius, Bengt

Ingår i Annals of Oncology, s. 400-402, 2008

• DOI för Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

Sørbye, Halfdan; Berglund, Åke; Tveit, Kjell Magne; Ogreid, Dagfinn et al.

Ingår i Acta Oncologica, s. 982-988, 2007

• DOI för Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid

Sørensen, Nanna M; Byström, Per; Christensen, Ib J; Berglund, Åke et al.

Ingår i Clinical Cancer Research, s. 4117-4122, 2007

• DOI för TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid

[Limit investigation in cancer of unknown primary site]

Berglund, Ake; Nygren, Peter; Hagberg, Hans; Pahlman, Lars et al.

Ingår i Lakartidningen, s. 2946-8, 2950, 2005

Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study.

Mahteme, H; Hansson, J; Berglund, Åke; Påhlman, Lars et al.

Ingår i Br J Cancer, s. 403-7, 2004

Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.

Sörbye, Halfdan; Glimelius, Bengt; Berglund, Ake; Fokstuen, Tone et al.

Ingår i J Clin Oncol, s. 31-8, 2004

Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer.

Byström, P; Frödin, J-E; Berglund, A; Wilking, Nils et al.

Ingår i Radiother Oncol, s. 171-5, 2004